A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Exclusion Criteria

• •1. Medical condition:
• •* Known hypersensitivity to monoclonal antibody (mAb) or investigational product (IP) component.
• •* Acute illness including fever on the day prior to or day of dosing.
• •* Any other significant disease increase the risk to participant study.
• •2. Laboratory related:
• •* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.0 × upper limit of normal (ULN), alkaline phosphatase (ALP) \> 1.5 × ULN, or TBL (total bilirubin) \> 1.5 × ULN (unless due to Gilbert's syndrome).
• •* Serum creatinine \> 176 μmol/L.
• •* Haemoglobin \< 10g/dL.
• •* Platelet count \< 100 × 10\^3/μL.
• •* White blood cell count \< 3.5 × 10\^3/μL or neutrophil count \< 1.5 × 10\^3/μL.
• •* Other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results.
• •3. COVID-19 infection history/any receipt of mAb indicated for COVID-19.
• •4. Prior/concomitant treatment: Receipt of any investigational product within 90 days or 5 antibody half-lives (whichever is longer) prior to Day 1